30937462|t|Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers.
30937462|a|PURPOSE: We investigated the frequency and clinical significance of amyloid beta (Abeta) positivity on PET in patients with cerebral amyloid angiopathy (CAA). METHODS: We recruited 65 patients who met the modified Boston criteria for probable CAA. All underwent amyloid PET, MRI, APOE genotyping and neuropsychological testing, and we obtained information on MRI markers of CAA and ischemic cerebral small-vessel disease (CSVD). We investigated the CAA/ischemic CSVD burden and APOE genotypes in relation to Abeta positivity and investigated the effect of Abeta positivity on longitudinal cognitive decline. RESULTS: Among the 65 CAA patients, 43 (66.2%) showed Abeta PET positivity (Abeta+). Patients with Abeta+ CAA had more lobar microbleeds (median 9, interquartile range 2-41, vs. 3, 2-8; P = 0.045) and a higher frequency of cortical superficial siderosis (34.9% vs. 9.1%; P = 0.025), while patients with Abeta- CAA had more lacunes (1, 0-2, vs. 0, 0-1; P = 0.029) and a higher frequency of severe white matter hyperintensities (45.5% vs. 20.9%; P = 0.040). The frequency of epsilon4 carriers was higher in Abeta+ patients (57.1%) than in Abeta- patients (18.2%; P = 0.003), while the frequency of epsilon2 carriers did not differ between the two groups. Finally, Abeta positivity was associated with faster decline in multiple cognitive domains including language (P < 0.001), visuospatial function (P < 0.001), and verbal memory (P < 0.001) in linear mixed effects models. CONCLUSION: Our findings suggest that a significant proportion of patients with probable CAA in a memory clinic are Abeta- on PET. Abeta positivity in CAA patients is associated with a distinct pattern of CSVD biomarker expression, and a worse cognitive trajectory. Abeta positivity has clinical relevance in CAA and might represent either advanced CAA or additional Alzheimer's disease neuropathological changes.
30937462	25	37	amyloid beta	Gene	351
30937462	52	60	patients	Species	9606
30937462	75	102	cerebral amyloid angiopathy	Disease	MESH:D016657
30937462	180	192	amyloid beta	Gene	351
30937462	194	199	Abeta	Gene	351
30937462	222	230	patients	Species	9606
30937462	236	263	cerebral amyloid angiopathy	Disease	MESH:D016657
30937462	265	268	CAA	Disease	MESH:D016657
30937462	296	304	patients	Species	9606
30937462	355	358	CAA	Disease	MESH:D016657
30937462	374	381	amyloid	Disease	MESH:C000718787
30937462	392	396	APOE	Gene	348
30937462	486	489	CAA	Disease	MESH:D016657
30937462	494	532	ischemic cerebral small-vessel disease	Disease	MESH:D059345
30937462	534	538	CSVD	Disease	MESH:D059345
30937462	561	564	CAA	Disease	MESH:D016657
30937462	565	573	ischemic	Disease	MESH:D002545
30937462	574	578	CSVD	Disease	MESH:D059345
30937462	590	594	APOE	Gene	348
30937462	620	625	Abeta	Gene	351
30937462	668	673	Abeta	Gene	351
30937462	701	718	cognitive decline	Disease	MESH:D003072
30937462	742	745	CAA	Disease	MESH:D016657
30937462	746	754	patients	Species	9606
30937462	774	779	Abeta	Gene	351
30937462	796	801	Abeta	Gene	351
30937462	805	813	Patients	Species	9606
30937462	819	824	Abeta	Gene	351
30937462	826	829	CAA	Disease	MESH:D016657
30937462	845	856	microbleeds	Disease	
30937462	952	973	superficial siderosis	Disease	MESH:D012806
30937462	1009	1017	patients	Species	9606
30937462	1023	1028	Abeta	Gene	351
30937462	1030	1033	CAA	Disease	MESH:D016657
30937462	1043	1050	lacunes	Disease	
30937462	1116	1145	white matter hyperintensities	Disease	MESH:D056784
30937462	1225	1230	Abeta	Gene	351
30937462	1232	1240	patients	Species	9606
30937462	1257	1262	Abeta	Gene	351
30937462	1264	1272	patients	Species	9606
30937462	1382	1387	Abeta	Gene	351
30937462	1659	1667	patients	Species	9606
30937462	1682	1685	CAA	Disease	MESH:D016657
30937462	1709	1714	Abeta	Gene	351
30937462	1724	1729	Abeta	Gene	351
30937462	1744	1747	CAA	Disease	MESH:D016657
30937462	1748	1756	patients	Species	9606
30937462	1798	1802	CSVD	Disease	MESH:D059345
30937462	1859	1864	Abeta	Gene	351
30937462	1902	1905	CAA	Disease	MESH:D016657
30937462	1942	1945	CAA	Disease	MESH:D016657
30937462	1960	1979	Alzheimer's disease	Disease	MESH:D000544
30937462	Association	MESH:D012806	351
30937462	Association	MESH:D056784	351
30937462	Association	MESH:D003072	351
30937462	Association	MESH:D016657	351

